https://scholars.lib.ntu.edu.tw/handle/123456789/503471
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Huang S.-H. | en_US |
dc.contributor.author | SHU-WEN LIN | en_US |
dc.contributor.author | SUI-YUAN CHANG | en_US |
dc.contributor.author | Lin Y.-T. | en_US |
dc.contributor.author | HSIN-YUN SUN | en_US |
dc.contributor.author | Liu W.-C. | en_US |
dc.contributor.author | Su Y.-C. | en_US |
dc.contributor.author | CHIEN-CHING HUNG | en_US |
dc.contributor.author | SHAN-CHWEN CHANG | en_US |
dc.creator | Huang S.-H.;Lin S.-W.;Sui-Yuan Chang;Lin Y.-T.;Sun H.-Y.;Liu W.-C.;Su Y.-C.;Hung C.-C.;Chang S.-C. | - |
dc.date.accessioned | 2020-06-18T08:25:50Z | - |
dc.date.available | 2020-06-18T08:25:50Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1684-1182 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/503471 | - |
dc.description.abstract | Background: Optimal efavirenz (EFV) dose that minimizes adverse effects while maintaining efficacy has yet to be elucidated. With a therapeutic drug monitoring (TDM)-guided strategy, we assessed the effectiveness of half-a-tablet EFV plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) in HIV-infected Taiwanese who had achieved viral suppression with full-dose (600 mg) EFV. Methods: HIV-infected adults receiving EFV-containing regimens who had plasma mid-dose EFV concentration (C12) ?2.0 mg/L and had plasma HIV RNA load (PVL) <200 copies/mL were enrolled in this single-arm, open-label study by reducing EFV to half-a-tablet daily. The primary endpoint was PVL <50 copies/ml in an intention-to-treat (ITT) population at week 48. The secondary endpoints were the plasma EFV C12, the proportion of patients with plasma EFV C12 <1.0 mg/L, PVL <50 copies/ml at week 96 and week 144. Results: Between April 2013 and September 2016, 203 patients (93.6% male; median age, 39.0 years) were enrolled. The median EFV C12 before switch was 2.80 mg/L (interquartile range (IQR), 2.41–3.73), which decreased to 1.59 mg/L (IQR, 1.23–2.03) after switch with a reduction of 47.4% (IQR, 38.3–55.5%). In ITT analysis, 93.6%, 92.3% and 87.3% of the patients achieved PVL <50 copies/ml at weeks 48, 96 and 144, respectively. More than 70% of the patients reported alleviation of EFV-associated adverse effects following the switch. Conclusion: Under the guidance of TDM, switch to half-a-tablet EFV plus 2 NRTIs is effective in maintaining viral suppression in HIV-infected Taiwanese with EFV C12 ? 2.0 mg/L. ? 2018 | - |
dc.relation.ispartof | Journal of Microbiology, Immunology and Infection | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | abacavir; efavirenz; emtricitabine; lamivudine; RNA directed DNA polymerase inhibitor; tenofovir disoproxil; anti human immunodeficiency virus agent; benzoxazine derivative; efavirenz; RNA directed DNA polymerase inhibitor; adult; antiretroviral therapy; Article; clinical trial; drug blood level; drug efficacy; drug monitoring; female; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; intention to treat analysis; maintenance therapy; major clinical study; male; nonhuman; prospective study; tablet; Taiwanese; virus load; administration and dosage; combination drug therapy; Human immunodeficiency virus 1; middle aged; sustained virologic response; tablet; Adult; Anti-HIV Agents; Benzoxazines; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Sustained Virologic Response; Tablets; Viral Load | - |
dc.title | Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jmii.2018.05.001 | - |
dc.identifier.pmid | 29884449 | - |
dc.identifier.scopus | 2-s2.0-85047925026 | - |
dc.relation.pages | 60-68 | - |
dc.relation.journalvolume | 53 | - |
dc.relation.journalissue | 1 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.dept | Pharmacy-NTUCC | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Tropical Medicine and Parasitology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Office of the Vice President | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.orcid | 0000-0002-9940-0850 | - |
crisitem.author.orcid | 0000-0002-6009-6724 | - |
crisitem.author.orcid | 0000-0003-0074-7721 | - |
crisitem.author.orcid | 0000-0001-7345-0836 | - |
crisitem.author.orcid | 0000-0001-6505-4139 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | Administrative Unit | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。